News

enews header for website

Enjoy the latest news related to the INTERCEPT Blood System, pathogen reduction system.


Customer News

8/18/16 - "ThedaCare Receives New Platelet Product" - ThedaCare.org

8/10/16 - "Bonfils adds new layer of safety to reduce transfusion risk" - CBS Denver - Channel 4 News

7/20/16 - "Bonfils/local hospital to provide local patients added layer of safety" - Bonfils Blood Center (CO) website

6/27/16 - "Pathogen reduction technology funding approved, ASBP on the forefront of deployment" - Armed Services Blood Program (ASBP) newsletter

4/25/16 - "Pathogen reduction technology helps combat blood borne disease"- Armed Services Blood Program (ASBP) newsletter


Industry News

9/12/16 - San Francisco Business Times - How this East Bay company is helping squash Zika

8/29/16 - Wired - Testing for Zika Isn’t the Only Way to Keep the Blood Supply Safe

7/19/16 - Fox Illinois News Team - Zika Virus Safety

7/14/16 - SF Chronicle - Concord's Cerus helps ensure blood safety for Rio Olympics

6/20/16 - Reuters - US to help fund technology to eliminate Zika in blood supply

2/16/16 - NYTimes - FDA Issues Zika Virus Guidelines for Blood Supply

9/28/15 - Wall Street Journal - The Rising Risk of a Contaminated Blood Supply; Amid new pathogens and cost pressures, efforts are under way to keep patients safe

5/14/15 - New England Journal of Medicine article published – The Safety of the Blood Supply: Time to Raise the Bar

4/27/15 - Cerus to Present at AABB Symposium on Pathogen-Reduced ComponentsCerus to Present at AABB Symposium on Pathogen-Reduced Components

for a complete archive of industry news, visit our corporate website at Cerus.com

 


Press Releases

8/29/16 - FDA's New Recommendation for Universal Zika Risk Reduction of Blood Components Includes Use of Pathogen Reduction

 2/9/16 - Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma

1/14/16 - AABB Authorizes Use of the INTERCEPT Blood System for Platelets to Reduce the Risk of Transfusion-Associated Graft Versus Host Disease

12/7/15 - Cerus and Shepeard Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma

12/4/15 - Cerus Announces Mississippi Valley Regional Blood Center Enters Into Agreement for the Use of INTERCEPT Platelets and Plasma

12/2/15 - Cerus Announces Collaboration Agreement With Haemonetics for the Use of Acrodose Platelet Kits With the INTERCEPT Blood System for Platelets

for a complete archive of press releases, visit our corporate website at Cerus.com

 


Newsletter Archive


2017    
August:  

New Contracts Enable Broad Adoption of INTERCEPT® Platelets in France

June:  

CMS Releases Outpatient Payment Rate Information for Pathogen Reduced Apheresis Platelets, Effective July 1, 2017

May:  

BARDA Releases Additional Funds to Support INTERCEPT Red Blood Cell System Development

April:  

CMS Releases Changes to HCPCS Code for Pathogen-Reduced Platelets

March:  

Patient Outcomes and Platelet Utilization in Massively Transfused Patients, Before and After INTERCEPT Implemenation

February:  

A Probable Case of West Nile Virus Transfusion Transmission

January:   

CBER Issues Guidance Agenda for 2017

     
2016    
December:  

BARDA Exercises Additional Contract Options Totaling 10M for Activities Related to its Planned Phase III Trial of the INTERCEPT Red Blood Cell System

November:  

Asymptomatic Blood Donors with Zika Virus Infection in Martinique

October:  

First U.S. Blood Center Submits Biologics License Application To The FDA to Allow For Interstate Export of INTERCEPT Platelet Components

September:  

FDA's New Recommendation for Universal Zika Risk Reduction of Blood Components Includes Use of Pathogen Reduction

August:  

US BARDA Funding Awarded to Cerus for up to $180 million to Advance its INTERCEPT Red Blood Cell Program

July:  

FDA Issues Advisory to Blood Centers Amidst Local Zika Infections in Florida

June:  

Health Canada Approves INTERCEPT Blood System for Plasma

May:  

Walter Reed National Military Medical Center Enters into Routine Use of the INTERCEPT Blood System

April:  

Widespread implementation of pathogen reduction technology recommended for maintaining a safe blood supply in an era of emerging pathogens

March:  

FDA Approves Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma

February:  

FDA Zika Guidance Allows Pathogen Reduction to Reduce Transfusion Risk and Maintain Blood Availability

January:   

AABB Authorizes Use of the INTERCEPT Blood System for Platelets to Reduce the Risk of Transfusion-Associated Graft versus Host Disease

     
2015    
December:  

Growing US Adoption of Pathogen Reduction – Additional Three Centers Enter into Agreement for Use of INTERCEPT

November:  

CMS Issues P-Codes for Hospital Outpatient Billing of PR Platelets and Plasma

September:  

Wall Street Journal Article Highlights Pathogen Reduction as a Means to Protect the Blood Supply

August:  

FDA to Publish Final Rule

July:  

SunCoast Blood Bank First in US to Provide Pathogen Reduced Platelets

June:  

NIH Enters Into Agreement for the Use of INTERCEPT® Platelets and Plasma

Newsletter

Our monthly pathogen reduction newsletter is designed to provide readers with the most up-to-date information related to the INTERCEPT Blood System for Platelets and Plasma pathogen reduction system – the first FDA pathogen reduction system approved in the United States.  

In each monthly issue you can look forward to:

  • Industry and product news
  • Summaries of recent publications
  • Suggested reading list
  • Calendar of events, including upcoming conferences and educational activities

Sign up today!

Please click here to join our mailing list today.